A Regulators Viewpoint
In this webinar, we describe current research efforts being developed in the FDA’s Division of Applied Regulatory Science (CDER), for evaluating microphysiological systems while considering their potential use in drug development.
Staff Fellow (Biological Scientist)
FDA
Watch this webinar to learn:
- Challenges in using microphysiological systems as drug development tools
- Examples of evaluation efforts of systems as drug development tools
- Hepatic and cardiac systems
- Key contexts of use in drug evaluation for these systems
Microengineered in vitro platforms that enhance the physiology of the cellular microenvironment have been developed and improved in the last decade for modeling focused properties of several tissues or organs, which are not recreated with traditional in vitro cell culture systems.
Despite published advancements in modeling tissue physiology in vitro, microphysiological systems are not yet routinely used in drug development.
FDA's initial projects have been focused on heart and liver systems and we are now expanding to other organ systems of relevance for evaluating drug effects.
Visit cn-bio.com for more information & news
